Compare CVS Health Corp (CVS) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs KeyCorp — how do they compare? CVS Health Corp trades at $86.52 (market cap $112.29B), while KeyCorp trades at $19.89 (market cap $21.45B). The key difference: CVS Health Corp is far larger — about 5.2× KeyCorp's market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and KeyCorp for 66 Days on average.
| CVS | KEY | |
|---|---|---|
Market Cap | $112.29B | $21.45B |
Volume | 7,763,676 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $110.60 | $23.99 |
52-Week Low | $70.08 | $16.78 |
Typical Hold Time | 83 Days | 66 Days |
Enterprise Value | $174.64B | $34.63B |
Dividend Yield | 3.03% | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
KeyCorp (KEY) trades at $19.83, down 1.54% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent management appointments and a 2026 revenue outlook raise to 8% growth signal operational momentum. However, technical indicators show oversold conditions with RSI at 26.31 and bearish moving average signals.
KEY presents a value opportunity with attractive valuation metrics and consistent earnings performance. The 26% upside to consensus price target of $25.00 and 60.79% analyst buy rating support bullish sentiment. Risks include frozen dividend payments since 2023 and sensitivity to interest rate changes. The bank's aggressive share buyback program and improving net interest income provide catalysts for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
